STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
Appointment of Mr. Paul Chun to the Board of Directors
On December 8, 2016, upon the recommendation of the Nominating
and Corporate Governance Committee (the Nominating Committee) of
the Board of Directors (the Board) of Stellar Biotechnologies,
Inc. (the Company), the Board unanimously appointed Mr. Paul Chun
as a director of the Company for a term that commences
immediately and expires at the Companys 2017 Annual Meeting of
Shareholders, or until his earlier resignation or removal. Mr.
Chun was appointed to fill a vacancy on the Board resulting from
the December 1, 2016 resignation from the Board by Dr. Gregory T.
Baxter, who assumed the role of the Companys Executive Vice
President of Corporate Development on such date. Mr. Chun was
also appointed to serve as a member of the Audit Committee of the
Board.
There is no arrangement or understanding between Mr. Chun and any
other person to which Mr. Chun was selected as a director, and
there are no related party transactions involving Mr. Chun that
are reportable under Item 404(a) of Regulation S-K. There are no
material plans, contracts or arrangements to which Mr. Chun is a
party or in which he participates, nor has there been any
material amendment to any plan, contract or arrangement by virtue
of Mr. Chuns appointment.
The following is certain biographical information regarding Mr.
Chun:
Paul Chun is a Managing Partner of Eldred
Advisors LLC, a life sciences advisory firm he founded in May
2016. From November 2015 to April 2016, he served as Director of
Strategy and Corporate Development at Kiromic, LLC. From May 2011
to October 2015, Mr. Chun served as a life sciences principal
with Westwicke Partners, LLC, a capital markets advisory firm.
During his tenure at Westwicke,he supported the capital markets
and investor engagement objectives of private and public
biopharma companies, including the support of multiple initial
public offerings and other strategic transactions. Prior to
Westwicke,heheld various roles in investment research and
corporate finance, including at Amgen, Inc.,Tavistock Life
Sciences, and Goldman, Sachs Co. He received his bachelors in
biological sciences from Columbia University. Mr. Chun has broad
experience in therapeutics development and commercialization,
valuation, corporate development and finance.
Among other experience, qualifications, attributes and skills,
Mr. Chuns broad experience in therapeutics development and
commercialization, valuation, corporate development and finance
led to the conclusion of our Nominating Committee and our full
Board that he is qualified to serve as a director of the Company.
Appointment of Charles V. Olson, D.Sc. to the Board of
Directors
On December 8, 2016, upon the recommendation of the Nominating
Committee, and in accordance with the Articles of the Company,
the Board voted to increase the size of the Board by one seat and
appointed Charles V. Olson, D.Sc. to the Board to fill a vacancy
on the Board resulting from such increase in the size of the
Board. Dr. Olson will serve for a term that commences immediately
and expires at the 2017 Annual Meeting of Shareholders, or until
his earlier resignation or removal.
There is no arrangement or understanding between Dr. Olson and
any other person to which Dr. Olson was selected as a director,
and there are no related party transactions involving Dr. Olson
that are reportable under Item 404(a) of Regulation S-K. There
are no material plans, contracts or arrangements to which Dr.
Olson is a party or in which he participates nor has there been
any material amendment to any plan, contract or arrangement by
virtue of Dr. Olsons appointment.
The following is certain biographical information regarding Dr.
Olson:
Charles V. Olson, D.Sc. currently serves as
Chief Technology Officer at Anthera Pharmaceuticals Inc.
(Anthera). Dr. Olson has served with Anthera in various roles
since April 2010. He has also been a Principal Biotechnology
Consultant for Compass Biotechnology LLC since 2006. Dr. Olson
previously held senior and executive management positions at NGM
Bioharmaceuticals Inc, Coherus BioSciences Inc, Nexbio Inc., Cell
Genesys, Inc., Biomarin Pharmaceuticals, Inc, and Onyx
Pharmaceuticals, Inc. After graduate school, Dr. Olson was a
Research Scientist at Kaiser Hospitals, followed by Scientist and
Senior Scientist positions at Genentech and Bayer, respectively.
He holds a B.A. in biology and chemistry from Westmont College,
an M.A. in chemistry from the University of California at Santa
Barbara and a D.Sc. in biochemistry. Dr. Olson has served as a
member of the Companys scientific advisory board since June 2014.
Among other experience, qualifications, attributes and skills,
Dr. Olsons extensive scientific, manufacturing operations,
process development and senior management experience in the
biopharmaceutical industry led to the conclusion of our
Nominating Committee and our full Board that he is qualified to
serve as a director of the Company.
| Item 8.01. | Other Events. |
On December 9, 2016, the Company issued a press release
announcing the appointments of Mr. Chun and Dr. Olson. A copy of
the press release is attached hereto as Exhibit 99.1
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
| Exhibit No. | Description | |
| 99.1 |
Press release issued by Stellar Biotechnologies, Inc. dated December 9, 2016. |
About STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT)
Stellar Biotechnologies, Inc. (Stellar) is a biotechnology company. The Company is engaged in the aquaculture, research and development, manufacture and commercialization of Keyhole Limpet Hemocyanin (KLH) protein. KLH is a high molecular weight and immune-stimulating protein. It operates under the brand name Stellar KLH. Its products include Stellar KLH protein in various grades, formulations and configurations for both clinical and preclinical applications. Stellar KLH can be used for therapeutic vaccine conjugation, as a carrier molecule in immunotherapies and as an immune stimulant in immunotoxicology applications. KLH can be used as an active pharmaceutical ingredient and combined with a disease-targeting agent to create immunotherapies targeting cancer, immune disorders, Alzheimer’s disease and inflammatory diseases, or it can be used as a finished, injectable product in the immunodiagnostic market for measuring immune response in patients and research settings. STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) Recent Trading Information
STELLAR BIOTECHNOLOGIES, INC. (NASDAQ:SBOT) closed its last trading session up +0.05 at 2.20 with 72,658 shares trading hands.